Asthma and Chronic Obstructive Pulmonary Disease (COPD) can be effectively treated with dry powder inhalers (DPIs), which are commonly used for pulmonary medication delivery. In order to optimize medicine formulation, particle engineering, and excipient selection, powder technology is essential. The powder's qualities, such as its size, shape, flowability, and surface features, are critical to the effectiveness of DPIs. Drug dispersion and deposition in the lungs are improved by designing carrier particles with regulated surface texture and aerodynamic characteristics. Improvements in powder processing methods like surface coating, spray drying, and micronization have increased the homogeneity of particles and the effectiveness of medication administration. Additionally, to improve dosage emission and consistency, the cohesive and adhesive forces between drug particles and carriers can be adjusted. Powder technology advancements also make it easier to create high-performance DPIs that can deliver biologics and small-molecule medications. Pharmaceutical scientists can improve patient compliance and treatment efficacy by concentrating on enhancing powder characteristics and device interactions. The significance of powder engineering in DPI design is emphasized in this review, along with how it contributes to better treatment results and efficient pulmonary drug delivery.
Tiwari et al. (Wed,) studied this question.